Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (iv) IL2

被引：0
|
作者：
Escudier, B [1 ]
Rossi, JF [1 ]
Ravaud, A [1 ]
Savary, J [1 ]
Pignard, K [1 ]
Negrier, S [1 ]
机构：
[1] CTR LEON BERARD,FRANCH CANC CTR FEDERAT,CTR COORDINATING,IMMUNOTHERAPY GRP,F-69373 LYON,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [31] THE EFFECTS OF PROLONGED TREATMENT OF PATIENTS WITH ADVANCED CANCER WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 (IL2)
    STEIN, RC
    MALKOWSKA, V
    MORGAN, S
    ANISZEWSKI, C
    GALAZKA, A
    BEVAN, D
    GORDONSMITH, EC
    COOMBES, RC
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 501 - 501
  • [32] COLLABORATION OF INTERLEUKIN 2(IL2) AND INTERFERON-GAMMA (IFN-GAMMA) IN THE INDUCTION OF HUMAN ACTIVATED KILLER (AK) CELLS
    ITOH, K
    TILDEN, A
    BALCH, CM
    FEDERATION PROCEEDINGS, 1985, 44 (05) : 1536 - 1536
  • [33] EFFECTS OF CD2 PERTURBATION ON INTERLEUKIN-2 (IL2) AND SURFACE IL2 RECEPTOR (IL2R) IN ANTI-CD3-INDUCED T-CELL ACTIVATION
    STOHL, W
    LINKERISRAELI, M
    FASEB JOURNAL, 1988, 2 (06): : A1660 - A1660
  • [34] HIGH-DOSE INTERLEUKIN-2 (HD IL2) ARMED WITH PATHOLOGY-BASED SELECTION CRITERIA: A REAL OPTION IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) AFTER TARGETED THERAPY
    Chow, S.
    Galvis, V.
    Evans, M.
    Chan, K.
    Spencer-Shaw, A.
    Leach, R.
    Keene, K.
    Shablak, A.
    Shanks, J.
    Thistlethwaite, F.
    Hawkins, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [35] Interleukin-2 (IL-2), interferon-alpha (IFN-alpha), 5-fluorouracil (5-FU) and vinblastine (VBL) for metastatic renal cell carcinoma (MRCC): A clinical and immunological study
    Gez, E
    Rubinov, R
    Mekori, T
    Struminger, L
    Skigin, R
    Keren, S
    Haim, N
    Kuten, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 388 - 388
  • [36] ACUTE RENAL-FAILURE DURING INTERLEUKIN-2 (IL2) TREATMENT - AN INTRINSIC RENAL LESION
    SHALMI, CL
    DUTCHER, JP
    FEINFELD, DA
    CHUN, KJ
    SALEEMI, KR
    FREEMAN, LM
    LYNN, RI
    WIERNIK, PH
    CLINICAL RESEARCH, 1989, 37 (03): : A862 - A862
  • [37] IMMUNOLOGICAL MODIFICATIONS INDUCED INVIVO AND INVITRO BY IL2 IN PATIENTS WITH METASTATIC RENAL-CARCINOMA AND NEURO-BLASTOMA
    FAVROT, MC
    COMBARET, V
    COZE, C
    PHILIP, I
    COCHAT, P
    MERCATELLO, A
    FLORET, D
    PHILIP, T
    LYMPHOKINE RESEARCH, 1988, 7 (03): : 295 - 295
  • [38] Capecitabine in combination with interferon-alpha in interleukin-2-refractory metastatic renal cell carcinoma (MRCC)
    Demidov, L. V.
    Tsimafeyeu, I. V.
    Naidzionak, U. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice
    Baumgart, DC
    Olivier, WA
    Reya, T
    Peritt, D
    Rombeau, JL
    Carding, SR
    CELLULAR IMMUNOLOGY, 1998, 187 (01) : 52 - 66
  • [40] INDOMETHACIN (IND) ATTENUATES RENAL TOXICITY AND ADVERSE METABOLIC EFFECTS OF SYSTEMIC INTERLEUKIN-2 (IL2) ADMINISTRATION IN PATIENTS WITH METASTATIC CANCER
    RUBINGER, D
    DJABARAH, R
    HITE, Y
    POPOVTZER, MM
    SHILONI, E
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 403 - 403
12345